Ling Dai, Mengjun Deng, Kena Chen, Xueping Chen, Junjie Li
{"title":"Ultrasensitive Detection of FLT3-ITD Mutations via Primer Competition Enhanced Mutant Accumulation","authors":"Ling Dai, Mengjun Deng, Kena Chen, Xueping Chen, Junjie Li","doi":"10.1021/acs.analchem.4c04750","DOIUrl":null,"url":null,"abstract":"The in-frame internal tandem duplication of the FLT-3 gene (FLT3-ITD), a prevalent genetic aberration, significantly contributes to treatment failure and poor prognosis in acute myeloid leukemia (AML). A robust and cost-effective assay for minimal residual disease (MRD) detection in FLT3-ITD<sup>+</sup> AML is crucial for guiding therapeutic decisions. However, current MRD monitoring methodologies for FLT3-ITD<sup>+</sup> patients are limited by sensitivity and adaptability, particularly for dynamically quantifying complex and heterogeneous FLT3-ITD mutations. In this study, we developed a primer competition enhanced mutation accumulation (PCEMA) technique designed to selectively enrich FLT3-ITD in the context of abundant wild-type alleles. By integrating the PCEMA with capillary electrophoresis, we significantly improved the discrimination between mutant and wild-type genes, increasing the minimum detectable sensitivity to 0.001%, comparable to next-generation sequencing. The competitive amplification between ITD-specific and universal primers facilitated the selective enrichment of mutant alleles, enabling highly sensitive and specific real-time FLT3-ITD mutation monitoring. We thoroughly evaluated the analytical performance and adoptability of the PCEMA technique in conjunction with quantitative fluorescent PCR (qPCEMA). Our results demonstrated that qPCEMA quantitatively differentiates FLT3-ITD with a mutation frequency below 0.1%, offering an effective, rapid, and reliable method for long-term FLT3-ITD monitoring in clinical AML patients. The PCEMA technique, characterized by its robustness, sensitivity, specificity, timeliness, and adoptability, presents a promising alternative for clinical FLT3-ITD mutation detection. It is anticipated to provide significant technical support for timely diagnosis, prognosis assessment, drug evaluation, and personalized treatment of AML patients, with substantial potential for clinical application.","PeriodicalId":27,"journal":{"name":"Analytical Chemistry","volume":"58 1","pages":""},"PeriodicalIF":6.7000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Analytical Chemistry","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1021/acs.analchem.4c04750","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, ANALYTICAL","Score":null,"Total":0}
引用次数: 0
Abstract
The in-frame internal tandem duplication of the FLT-3 gene (FLT3-ITD), a prevalent genetic aberration, significantly contributes to treatment failure and poor prognosis in acute myeloid leukemia (AML). A robust and cost-effective assay for minimal residual disease (MRD) detection in FLT3-ITD+ AML is crucial for guiding therapeutic decisions. However, current MRD monitoring methodologies for FLT3-ITD+ patients are limited by sensitivity and adaptability, particularly for dynamically quantifying complex and heterogeneous FLT3-ITD mutations. In this study, we developed a primer competition enhanced mutation accumulation (PCEMA) technique designed to selectively enrich FLT3-ITD in the context of abundant wild-type alleles. By integrating the PCEMA with capillary electrophoresis, we significantly improved the discrimination between mutant and wild-type genes, increasing the minimum detectable sensitivity to 0.001%, comparable to next-generation sequencing. The competitive amplification between ITD-specific and universal primers facilitated the selective enrichment of mutant alleles, enabling highly sensitive and specific real-time FLT3-ITD mutation monitoring. We thoroughly evaluated the analytical performance and adoptability of the PCEMA technique in conjunction with quantitative fluorescent PCR (qPCEMA). Our results demonstrated that qPCEMA quantitatively differentiates FLT3-ITD with a mutation frequency below 0.1%, offering an effective, rapid, and reliable method for long-term FLT3-ITD monitoring in clinical AML patients. The PCEMA technique, characterized by its robustness, sensitivity, specificity, timeliness, and adoptability, presents a promising alternative for clinical FLT3-ITD mutation detection. It is anticipated to provide significant technical support for timely diagnosis, prognosis assessment, drug evaluation, and personalized treatment of AML patients, with substantial potential for clinical application.
期刊介绍:
Analytical Chemistry, a peer-reviewed research journal, focuses on disseminating new and original knowledge across all branches of analytical chemistry. Fundamental articles may explore general principles of chemical measurement science and need not directly address existing or potential analytical methodology. They can be entirely theoretical or report experimental results. Contributions may cover various phases of analytical operations, including sampling, bioanalysis, electrochemistry, mass spectrometry, microscale and nanoscale systems, environmental analysis, separations, spectroscopy, chemical reactions and selectivity, instrumentation, imaging, surface analysis, and data processing. Papers discussing known analytical methods should present a significant, original application of the method, a notable improvement, or results on an important analyte.